| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/50-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | GHR; Growth hormone receptor; GH receptor; Somatotropin receptor |
| Entrez GeneID | 2690 |
| WB Predicted band size | Calculated MW: 72 kDa; Observed MW: 140 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human Growth hormone receptor |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于生长激素受体(Growth Hormone Receptor, GHR)抗体的代表性文献摘要，供参考：
---
1. **文献名称**: *"Monoclonal Antibodies to the Growth Hormone Receptor: A Novel Approach to Studying Receptor Structure and Function"*
**作者**: Frank SJ et al.
**摘要**: 该研究开发了针对GHR胞外结构域的单克隆抗体，用于分析受体构象变化与生长激素(GH)信号传导的关系。抗体通过阻断GH结合或稳定受体二聚化，揭示了GHR激活的关键机制，并证实其在体外模型中调节STAT5信号通路的能力。
---
2. **文献名称**: *"Targeting Growth Hormone Receptor in Human Melanoma Cells with a Neutralizing Antibody"*
**作者**: Basu R et al.
**摘要**: 研究报道了一种中和性抗体(GHRAb)在黑色素瘤细胞中的作用。结果显示，抗体通过抑制GHR介导的JAK2-STAT3通路，显著降低肿瘤细胞增殖和迁移，提示GHR抗体可能作为癌症治疗的潜在靶向策略。
---
3. **文献名称**: *"A Nanobody-Based Approach to Modulate Growth Hormone Receptor Activity In Vivo"*
**作者**: Van Lenthe S et al.
**摘要**: 该研究利用基因工程纳米抗体(VHH)靶向GHR的跨膜区，在小鼠模型中验证了其调节代谢的功能。抗体通过干扰GHR二聚化，降低胰岛素样生长因子-1(IGF-1)水平，为代谢性疾病(如糖尿病)提供了新的干预思路。
---
如需具体文章，建议通过 **PubMed** 或 **Google Scholar** 检索关键词“Growth Hormone Receptor antibody”或相关作者名，获取全文信息。
Growth hormone receptor (GHR) antibodies are biological tools or therapeutic agents targeting the GHR, a transmembrane protein critical for mediating growth hormone (GH) signaling. GHR belongs to the cytokine receptor superfamily and consists of an extracellular hormone-binding domain, a transmembrane segment, and an intracellular signaling domain. Upon GH binding, GHR dimerizes and activates JAK2-STAT signaling pathways, regulating growth, metabolism, and cell differentiation.
Antibodies against GHR can act as either agonists or antagonists. Agonistic antibodies mimic GH by stabilizing active receptor conformations, potentially treating conditions like growth hormone deficiency. Antagonistic antibodies block GH binding or receptor dimerization, inhibiting downstream signaling. These are explored for diseases driven by excessive GH activity, such as acromegaly or certain cancers where GH pathways promote tumor growth.
Monoclonal anti-GHR antibodies, like pegvisomant (a modified GH analog), are FDA-approved for acromegaly. Research also focuses on developing selective antibodies to modulate tissue-specific GHR activity, addressing metabolic disorders or aging-related conditions. Additionally, GHR antibodies serve as diagnostic tools to quantify receptor expression in cancers or study GH signaling mechanisms in research. Challenges include optimizing antibody specificity to minimize off-target effects and ensuring long-term safety in therapeutic applications.
×
